Published in Antimicrob Agents Chemother on April 01, 2002
Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther (2009) 1.41
A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br J Clin Pharmacol (2005) 1.28
The blood parasite Haemoproteus reduces survival in a wild bird: a medication experiment. Biol Lett (2010) 1.15
Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin. Br J Clin Pharmacol (2005) 1.09
First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone. Antimicrob Agents Chemother (2008) 1.07
Dried whole plant Artemisia annua as an antimalarial therapy. PLoS One (2012) 1.04
Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother (2012) 0.98
Auto-induction of phase I and phase II metabolism of artemisinin in healthy Chinese subjects after oral administration of a new artemisinin-piperaquine fixed combination. Malar J (2014) 0.83
Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study. Clin Ther (2011) 0.82
Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells. Mol Carcinog (2015) 0.79
Retrospective analysis of artemisinin pharmacokinetics: application of a semiphysiological autoinduction model. Br J Clin Pharmacol (2007) 0.78
An investigation of the auto-induction of and gender-related variability in the pharmacokinetics of dihydroartemisinin in the rat. Malar J (2012) 0.78
Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers. J Antimicrob Chemother (2016) 0.77
Pharmacokinetic study of gallocatechin-7-gallate from Pithecellobium clypearia Benth. in rats. Acta Pharm Sin B (2015) 0.75
Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers. Malar J (2016) 0.75
Effects of artemisinin derivatives on malaria transmissibility. Lancet (1996) 7.42
Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci (1999) 4.52
Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev (1996) 3.26
Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans R Soc Trop Med Hyg (1996) 1.90
Chloroquine increases Plasmodium falciparum gametocytogenesis in vitro. Parasitology (1999) 1.88
Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab Dispos (1998) 1.67
Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin Pharmacol Ther (1998) 1.46
Distinction of recrudescences from new infections by PCR-RFLP analysis in a comparative trial of CGP 56 697 and chloroquine in Tanzanian children. Trop Med Int Health (1998) 1.43
Comparison of oral artemether and mefloquine in acute uncomplicated falciparum malaria. Lancet (1992) 1.34
Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria. Am J Trop Med Hyg (1998) 1.29
Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. Trends Pharmacol Sci (1999) 1.25
Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics (1992) 1.18
Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br J Clin Pharmacol (1998) 1.14
Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses. Biopharm Drug Dispos (1998) 1.13
Use of saliva and capillary blood samples as substitutes for venous blood sampling in pharmacokinetic investigations of artemisinin. Eur J Clin Pharmacol (2000) 1.09
Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther (1998) 1.08
Use of artemisinin derivatives for the control of malaria. Med Trop (Mars) (1998) 1.07
Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol (2000) 0.99
Single-dose, comparative study of venous, capillary and salivary artemisinin concentrations in healthy, male adults. Am J Trop Med Hyg (1997) 0.95
Direct analysis of artemisinin in plasma and saliva using coupled-column high-performance liquid chromatography with a restricted-access material pre-column. J Chromatogr B Biomed Sci Appl (2000) 0.91
Plasma concentrations of artemether and its major plasma metabolite, dihydroartemisinin, following a 5-day regimen of oral artemether, in patients with uncomplicated falciparum malaria. Ann Trop Med Parasitol (1998) 0.88
Interindividual variability of coumarin 7-hydroxylation in a Turkish population. Eur J Clin Pharmacol (1994) 0.86
High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol (2007) 2.68
Pitfalls in estimating piperaquine elimination. Antimicrob Agents Chemother (2005) 1.79
Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol (2002) 1.38
Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Eur J Clin Pharmacol (2006) 1.31
A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br J Clin Pharmacol (2005) 1.28
Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Antimicrob Agents Chemother (2010) 1.27
The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop (2008) 1.19
Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J Pharmacokinet Pharmacodyn (2007) 1.16
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther (2003) 1.07
Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam Clin Pharmacol (2007) 1.04
In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol (2011) 0.98
A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Malar J (2012) 0.97
Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications. Br J Clin Pharmacol (2015) 0.96
Knowledge about sexually transmitted diseases in women among primary care physicians. Sex Transm Dis (2005) 0.94
Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur J Clin Pharmacol (2014) 0.92
Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy. AAPS J (2011) 0.92
Artemisinin and CYP2A6 activity in healthy subjects. Eur J Clin Pharmacol (2007) 0.90
Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol (2002) 0.90
Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat. J Pharmacokinet Pharmacodyn (2013) 0.87
A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn (2008) 0.83
Characterisation of the human liver in vitro metabolic pattern of artemisinin and auto-induction in the rat by use of nonlinear mixed effects modelling. Biopharm Drug Dispos (2003) 0.82
Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study. Clin Ther (2011) 0.82
HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. Clin Pharmacokinet (2011) 0.80
Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol (2004) 0.80
PXR variants and artemisinin use in Vietnamese subjects: frequency distribution and impact on the interindividual variability of CYP3A induction by artemisinin. Antimicrob Agents Chemother (2012) 0.79
Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies. Xenobiotica (2014) 0.77
External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients. AAPS J (2012) 0.77
Prediction of drug tissue to plasma concentration ratios using a measured volume of distribution in combination with lipophilicity. J Pharm Sci (2008) 0.77
The evaluation of CYP2B6 inhibition by artemisinin antimalarials in recombinant enzymes and human liver microsomes. Drug Metab Lett (2012) 0.77
Artemisinin--a possible CYP2B6 probe substrate? Biopharm Drug Dispos (2009) 0.76
A rapid and selective HPLC-UV method for the quantitation of efavirenz in plasma from patients on concurrent HIV/AIDS and tuberculosis treatments. Biomed Chromatogr (2013) 0.76
Effects of oral administration of synthesized delta-amides of eflornithine in the rat. Arzneimittelforschung (2010) 0.75
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients. J Pharmacokinet Pharmacodyn (2011) 0.75
Mono-, di- and trisubstituted derivatives of eflornithine: synthesis for in vivo delivery of DL-alpha-difluoromethylornithine in plasma. Arzneimittelforschung (2011) 0.75
A high-throughput LC-MS/MS assay for quantification of artesunate and its metabolite dihydroartemisinin in human plasma and saliva. Bioanalysis (2014) 0.75
Simultaneous enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.75
The Vietnamese Khin population harbors particular N-acetyltransferase 2 allele frequencies. Clin Chem (2007) 0.75